2 Oct 2018 07:00
2 October 2018
LEI No. 213800QIPVTK5ES5UU36
Scapa Group plc ("Scapa" or "the Group")
Completion of Acquisition of Systagenix Advanced Wound Dressing Facility in Gargrave
Entering a 5-year exclusive manufacturing and supply agreement
Further to the announcement made on 13 September 2018, Scapa Group plc (AIM: SCPA) is pleased to announce that its acquisition of the share capital of Systagenix Wound Management Manufacturing Limited completed on 1 October 2018. In addition, Scapa and Acelity have now entered into the exclusive five-year manufacturing and supply agreement for Systagenix advanced wound care products that are currently manufactured in the Gargrave facility, with immediate effect.
For further information:
Scapa Group plc Heejae Chae - Group Chief Executive Oskar Zahn - Chief Financial Officer
|
0161 301 7430 |
Numis Securities Limited (Nominated Adviser and Joint Broker) Richard Thomas/Mark Lander | 020 7260 1000 |
|
|
Berenberg (Joint Broker) Chris Bowman
Weber Shandwick Financial PR Nick Oborne |
020 3207 7800
020 7067 0000 |